Comparing two doses of olanzapine for nausea after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a lower dose of olanzapine (2.5 mg) works as well as the usual dose (5 mg) for preventing nausea and vomiting caused by high-dose melphalan chemotherapy. It is for people receiving their own stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive high-dose melphalan (a strong chemotherapy drug) and an autologous stem cell transplant (your own stem cells given back to you).
- You are not allergic to olanzapine.
- You have not had nausea or vomiting in the 24 hours before starting the study.
- You are not taking other antipsychotic medicines (like risperidone, quetiapine, clozapine, or similar drugs).
- You do not have chronic alcoholism.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two anti-nausea drug regimens (one with olanzapine, one with dexamethasone) to prevent delayed nausea and vomiting after a stem cell transplant for multiple myeloma. It aims to find which is better at controlling these side effects.
This study tests if the drug olanzapine (commonly used for nausea) can help prevent vomiting in people receiving moderately strong chemotherapy for the first time. It may be a good fit if you're about to start treatment with oxaliplatin, irinotecan, or carboplatin and haven't had severe nausea treatments before.
This trial tests if the drug olanzapine can help improve appetite in people with head and neck cancer who are getting chemotherapy and radiation. It aims to prevent or reduce weight loss during treatment.
This trial tests whether a medication called olanzapine can help reduce nausea and loss of appetite in patients receiving chemotherapy before surgery for stomach cancer. The goal is to help you feel better and maintain nutrition during your cancer treatment.
This trial tests a new anti-nausea medicine combination for breast cancer patients getting AC chemotherapy, specifically designed for those with diabetes, obesity, or other metabolic issues. It aims to reduce the need for steroids, which can be riskier for these patients.
This study tests whether olanzapine, a medication that can increase appetite, helps prevent severe appetite loss and muscle wasting in patients with ovarian or stomach cancer who are receiving chemotherapy before surgery. The goal is to help patients maintain nutrition and strength during treatment.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.